

## **Patient Group Conflict of Interest Declaration**

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

No.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

No.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

ompany
bbVie
mgen
stellas
straZeneca
ayer
MS
MC
isai
anssen
eo
illy
lerck
ovartis
fizer
oche

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Jackie Manthorne Position: President & CEO

Patient Group: Canadian Cancer Survivor Network

Date: October 21, 2017



## pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:			atient a	advocacy	Save Your Skin Foundation			
	Name o	f drug and inc	dication	under review:	Avelumab			
C	onflict	t of Intere	st Dec	clarations				
re po inf	view pro tential o formatio	ocess must disconflicts of information of the conflicts of information submitted.	close ar cerest tl Conflict	ny conflicts of int hat may influence	e pCODR process, all participants in the pCODR erest. Patient advocacy groups must declare any e or have the appearance of influencing the aration is requested for transparency — it does not acy group input.			
Ex	amples (	of conflicts of	interes	t include, but are	e not limited to:			
	ho • aff	noraria, gifts,	and sal	ary;	al industry e.g., educational or research grants, lationships with drug manufacturers or other interest			
Se	ction A:	Payment Re	ceived					
1.		Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?						
		Yes No						
	If no, please go to Section B							
2.	What f	What form of payment did this patient advocacy group receive? (Check all that apply.)						
		Operating Funds Royalties Gifts Honoraria		Program Funding website) Research/educa grants Sponsorship of E Other, please sp	tional			
3.	the bo	provide the rx below.  MD erck ovartis	sames of \$ \$ \$ \$ \$	f companies and	organizations and the amounts of the payments in			

Roche

## Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than
\$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in
the drug under review? If yes, please list in the table below.

NO			

## Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No			

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: Oct 24<sup>th</sup> 2017 Name: Kathleen Barnard Signature:\_\_\_\_\_